Psychological Medicine
November 1, 2024
L. Roldán, Teresa Sánchez‐Gutiérrez, I. Fernández-Arias et al.
Background Cannabis use and familial vulnerability to psychosis have been associated with social cognition deficits. This study examined the potential relationship between cannabis use and cognitive biases underlying social cognition and functioning in patients with first episode psychosis (FEP), their siblings, and controls. Methods We analyzed a sample of 543 participants with FEP, 203...
Psychological Medicine
May 9, 2024
J. Selten, Marta Di Forti, Diego Quattrone et al.
BACKGROUND We examined whether cannabis use contributes to the increased risk of psychotic disorder for non-western minorities in Europe. METHODS We used data from the EU-GEI study (collected at sites in Spain, Italy, France, the United Kingdom, and the Netherlands) on 825 first-episode patients and 1026 controls. We estimated the odds ratio (OR) of psychotic disorder for several groups of...
Psychological Medicine
May 4, 2023
Giulia Trotta, Victoria Rodriguez, Diego Quattrone et al.
Abstract Background Childhood adversity and cannabis use are considered independent risk factors for psychosis, but whether different patterns of cannabis use may be acting as mediator between adversity and psychotic disorders has not yet been explored. The aim of this study is to examine whether cannabis use mediates the relationship between childhood adversity and psychosis. Methods Data were...
Psychological Medicine
May 2, 2023
Edoardo Spinazzola, Diego Quattrone, Victoria Rodriguez et al.
Abstract Background While cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis. Methods We used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case–control study. 558 first-episode psychosis patients (FEPp) and 567...
Translational Psychiatry
August 10, 2021
Diego Quattrone, Ulrich Reininghaus, Anne Richards et al.
Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms...
Psychological Medicine
March 18, 2020
Diego Quattrone, Laura Ferraro, Giada Tripoli et al.
89 citations
Abstract Background Daily use of high-potency cannabis has been reported to carry a high risk for developing a psychotic disorder. However, the evidence is mixed on whether any pattern of cannabis use is associated with a particular symptomatology in first-episode psychosis (FEP) patients. Method We analysed data from 901 FEP patients and 1235 controls recruited across six countries, as part of...
Schizophrenia Bulletin
July 2, 2019
Laura Ferraro, Caterina la Cascia, Diego Quattrone et al.
25 citations
Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6...
The Lancet Psychiatry
May 1, 2019
Marta Di Forti, Diego Quattrone, Tom P. Freeman et al.
Summary Background Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder....